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Abstract
Background: Enhanced osteoblast-dependent osteoclastogenesis due to inhibition of Wnt/β-
catenin signaling in bone morphogenic protein (BMP)-driven osteoprogenitors has been repeatedly
implicated in the natural history of cancer-associated osteolytic lesions, but the mechanism of this
bone loss is poorly understood.
Methods: We examined the impact of secreted Wnt inhibitors from the Dickkopf (Dkk) family
on pluripotent mesenchymal cells undergoing BMP2-induced osteoblastic differentiation.
Results:  W e  f o u n d  t h a t  D k k 1  a n d  - 2  r e s t o r e d  t h e Wnt3a-dependent reduction of alkaline
phosphatase (ALP), Osterix and p53, indicating that mitigated Wnt/β-catenin signaling promotes
certain aspects of early osteoblastogenesis through the BMP-p53-Osterix-ALP axis. Dkk1 and -2
increased the expression of the osteoclast differentiation factors, receptor activator of NF-κB
ligand (RANKL) and macrophage-colony stimulating factor (M-CSF), upon stimulation with Wnt3a/
1,25-dihydroxyvitamine D3  and Wnt3a/BMP2, respectively. The decoy receptor of RANKL,
osteoprotegerin (OPG), was down regulated under the latter conditions. These findings indicated
that Dkk1 and -2 facilitate osteoclastogenesis by enhancing RANKL/RANK and M-CSF/c-Fms
interactions. Dkk4 weakly shared activities of Dkk-1 and -2, whereas Dkk3 was ineffective.
Conclusion:  Our results suggest that inhibited Wnt/β-catenin signaling in BMP2-induced
osteoprogenitors in vivo promotes, on balance, the heightened formation of osteoclasts. Focally
increased Dkk1 production by tumor cells in the bone may thus lead to focal bone loss.
Background
The development of bone-resorbing osteoclasts is strictly
dependent upon bone-forming osteoblasts and the bal-
anced activity of both cell types is crucial for skeletal
homeostasis [1,2]. Excess osteoclastic activity leading to
focal bone loss is a common feature of human cancer,
notably multiple myeloma (MM) [3]. Two factors sup-
plied by osteoblast lineage cells are of critical importance
for osteoclastogenesis: macrophage-colony stimulating
factor (M-CSF)1 and receptor activator of NF-κB ligand
(RANKL) [2]. M-CSF is required for proliferation and sur-
vival of osteoclast precursors, while RANKL is critical for
precursor differentiation into mature, multinucleated
osteoclasts. In addition to these positive regulators, oste-
Published: 30 October 2007
Molecular Cancer 2007, 6:71 doi:10.1186/1476-4598-6-71
Received: 8 September 2007
Accepted: 30 October 2007
This article is available from: http://www.molecular-cancer.com/content/6/1/71
© 2007 Fujita and Janz; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Molecular Cancer 2007, 6:71 http://www.molecular-cancer.com/content/6/1/71
Page 2 of 13
(page number not for citation purposes)
oblast lineage cells produce the major inhibitor of osteo-
clast differentiation, osteoprotegerin (OPG) [2]. Upon
secretion into the extracellular milieu, OPG acts as a decoy
receptor for RANKL, blocking the various signaling cas-
cades activated by binding of RANKL to its receptor on
pre-osteoclasts, RANK [4-6]. Altered expression of M-CSF,
RANKL and OPG in osteoprogenitors may facilitate can-
cer-associated osteolytic disease by promoting osteoblast-
dependent osteoclastogenesis.
Homeostatic bone remodeling requires coordinated inte-
gration of biological signals from numerous cellular sig-
nal transduction pathways including Wnt/β-catenin
signaling [7]. Wnt/β-catenin promotes new bone forma-
tion by functioning as a positive regulator of osteoblasts
[8-10] and, by up-regulating OPG [11-13] and down-reg-
ulating RANKL [12,14] on osteoprogenitors, negative reg-
ulator of osteoblast-dependent osteoclastogenesis. Wnt/
β-catenin signaling in the osteoblast lineage is activated
by binding of canonical Wnt ligands, such as Wnt3a, to a
membrane-bound receptor complex that consists of Friz-
zled and low-density-lipoprotein receptor-related protein
5/6 (LRP5/6). Canonical Wnt ligands inhibit the degrada-
tion of β-catenin in the cytoplasm, leading to transloca-
tion of β-catenin to the cell nucleus where it cooperates
with transcription factors of the T-cell factor/lymphoid
enhancer factor family in regulating target gene expression
[15,16]. In human beings, diminished and elevated Wnt/
β-catenin signaling due to loss-of-function and gain-of-
function mutations in LRP5 lead to osteoporosis [17] and
osteopetrosis [18,19], respectively. Both phenotypes were
accurately recapitulated in transgenic mouse models of
LRP function [20,21], providing further evidence of Wnt/
β-catenin's anabolic role in the bone.
Abnormal levels of secreted antagonists of Wnt signaling
have been shown to shift bone remodeling in both direc-
tions. One class of Wnt inhibitors that blocks Wnt ligand
binding to Frizzled includes secreted frizzled-related pro-
teins (sFrps), which block both the canonical (β-catenin
dependent) and the various non-canonical (β-catenin
independent) Wnt pathways [22]. Mice deficient in sFrp1
exhibit high bone mass [23], whereas over-expression of
sFrp2 has been implicated in the development of osteo-
lytic lesions in MM [24]. Another class of Wnt inhibitors
including Dickkopf (Dkk) proteins bind to LRP5/6 and
Kremen1/2. This leads to suppression of canonical Wnt
signaling but spares the non-canonical pathways [22].
Mice containing one wild type and one null allele of Dkk1
exhibit increased bone mass [25], whereas over-expres-
sion of DKK1 has been associated with osteolytic meta-
static bone disease in prostate carcinoma [26] and MM
[27]. These findings illustrate the significance of secreted
Wnt inhibitors to bone health.
Secreted bone morphogenic proteins (BMPs), such as
BMP2, are members of the transforming growth factor β
(TGF-β) superfamily that can induce new bone formation
in vivo [28]. BMP2 signaling begins with binding to serine/
threonine kinase receptors on the cell surface, continues
with phosphorylation of so-called restricted Smads form-
ing complexes with common Smad in the cytoplasm, and
culminates in the transcriptional activation of specific tar-
get genes in the nucleus [29]. Among the BMP2-induced
genes important for osteoblast development is the zinc
finger transcription factor, Osterix [30]. Upstream of
Osterix is the transcription factor Cbfa1, a crucial determi-
nant of the commitment of mesenchymal stem cells to
undergo osteoprogenitor differentiation [31]. Farther
upstream in this pathway is the cell cycle checkpoint pro-
tein and tumor suppressor, p53 [32]. Osteoblasts defi-
cient in p53 exhibit enhanced ability to promote
osteoblast-dependent osteoclastogenesis [32]. Noggin
prevents BMP2 receptor binding [29], providing a tool to
interrupt the BMP-p53-Cbfa1-Osterix axis in the osteob-
last lineage.
Cross talk of Wnt/β-catenin and BMP signaling is known
to play a role in the regulation of osteoblast differentia-
tion and function, but the molecular mechanism by
which Wnt/β-catenin influences BMP-induced osteoblast-
ogenesis and, by inference, osteoblast-dependent osteo-
clastogenesis, is poorly defined. Here we used
mesenchymal stem cells undergoing differentiation into
osteoprogenitors in vitro to evaluate the mechanism by
which Wnt3a/β-catenin modulates BMP2-driven pre-oste-
oblasts. Taking advantage of Wnt inhibitors from the
Dickkopf family and the BMP inhibitor, Noggin, we dem-
onstrated that inhibition of Wnt3a/β-catenin by Dkk-1
and -2 promotes certain aspects of osteoblast develop-
ment through the BMP2-p53-Osterix axis. The concomi-
tant up-regulation of M-CSF/RANKL and down-regulation
of OPG indicated, however, that Dkk-1 and -2 also have
the potential to promote osteoclastogenesis. The latter
view is in line with a large body of clinical evidence on
neoplasms constitutively expressing Dkk1 (MM, prostate
carcinoma), showing that, on balance, this canonical Wnt
inhibitor facilitates bone loss (osteolysis) in vivo.
Results
Dkk1 and -2 produced by mouse plasmacytoma cells 
reduce β-catenin in L indicator cells
To evaluate the role of mouse Dkk proteins in cancer-asso-
ciated focal bone lesions in mice, we generated four differ-
ent sublines of mouse plasmacytoma MOPC315.4 that
stably expressed Dkk1, -2, -3 or -4. Tumor cells were trans-
fected with retrovirus that contained a bi-cistronic expres-
sion vector encoding one of the Dkk proteins in
conjunction with the reporter, enhanced GFP. The
reporter was used for enriching GFP-expressing cells byMolecular Cancer 2007, 6:71 http://www.molecular-cancer.com/content/6/1/71
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flow sorting, which increased, in the case of Dkk1, the
fraction of GFP+ cells from 70% to 90%. Similar enrich-
ments were achieved with Dkk2, -3 and -4. All four Dkk
proteins were readily detected by Western blotting of
lysates of GFP+ tumor cells using either Ab to the FLAG
epitope (Fig. 1A top) or specific Ab to Dkk1, -2, -3 or -4
(Fig. 1A center). Western blotting with Ab to β-actin and
GFP showed that parental MOPC315.4 cells or cells trans-
fected with retrovirus expressing only GFP did not express
any detectable Dkk protein (Fig. 1A bottom). Real-time
PCR of Dkk1, -2, -3 and -4 mRNA levels confirmed the
negative immunoblotting data presented in Figure 1A
(not shown).
Western analysis of cell culture supernatants from the
above-described MOPC315.4 transfectants demonstrated
that all four Dkk proteins were secreted into the extracel-
lular milieu (Fig. 1B). All four Dkk's were readily detected
by antibody to the His6 tag (Fig. 1B top), FLAG (results not
shown) or specific epitopes on the Dkk1, -2, -3 or -4 pro-
teins (Fig. 1B bottom). MOPC315.4 cells left untreated or
transfected with retrovirus expressing only GFP did not
secrete Dickkopf protein (Fig. 1B, lanes labeled Parental
and Control, respectively). Just like human DKK secreted
by transient 293T human embryonic kidney cell transfect-
ants [33], the secreted mouse Dkk proteins appeared to
undergo post-translational modification including prote-
olytic cleavage and glycosylation, which produced dis-
tinct, highly reproducible bands on the immunoblots
(Fig. 1B and data not shown).
To investigate whether the secreted Dkk proteins func-
tioned as inhibitors of Wnt/β-catenin signaling, we per-
formed the β-catenin stabilization assay in L cells [34,35].
Stimulation of L cells with Wnt3a-CM (obtained from
Wnt3a-transfected L cells) resulted in a marked increase of
β-catenin compared to L cells stimulated with L-CM
(obtained from mock-transfected L cells), as shown in Fig-
ure 1C (compare lanes 3–4 with lanes 1–2). The Wnt3a-
dependent accumulation of β-catenin was reduced in cells
treated with Dkk1- or Dkk2-CM (obtained from trans-
fected MOPC315.4 cells) in a dose-dependent manner
(Fig. 1C and 1D). Dkk3-CM was ineffective, as expected,
whereas Dkk4-CM, which was marginally effective in
some experiments described below, was also ineffective in
these experiments (Fig. 1D). These results clearly demon-
strated that Dkk1 and -2 secreted by mouse plasmacytoma
cells functioned as canonical Wnt/β-catenin inhibitor.
Dkk1 and -2 inhibit Wnt3a-induced expression of ALP and 
osteocalcin (OCN)
To investigate the role of Dkk proteins in Wnt-induced
osteoblast differentiation in vitro, we took advantage of
cell lines C3H10T1/2 and C2C12. The former is a mouse
mesenchymal stem cell with differentiation potential
along several lineages including osteoprogenitors. The lat-
ter is a primitive mouse myoblast that can undergo differ-
entiation to preosteoblast-like cells. In both cell lines,
osteoblastic differentiation can be monitored by expres-
sion of ALP and OCN, two representatives of early and
late markers of osteoblast differentiation, respectively.
Treatment with Wnt3a led to a 5-fold increase in ALP
activity in C3H10T1/2 cells (Fig. 2A right, top bar), con-
firming a previous result under similar conditions [10].
Dkk1 and -2 secreted by MOPC315.4 cells attenuate Wnt3a/ β-catenin signaling in L cells Figure 1
Dkk1 and -2 secreted by MOPC315.4 cells attenuate Wnt3a/β-
catenin signaling in L cells. A, Constitutive expression of Dkk1-4 in sta-
ble transfectants of mouse plasmacytoma MOPC315.4. Total cell lysate 
(10 µg) was analyzed by Western blotting using Ab to FLAG, Dkk1-4 or 
GFP as indicated. β-actin levels (bottom) were determined as loading con-
trol. Untreated parental cells and cells transfected with GFP only (control) 
were included (bottom left). Protein size markers are indicated in kilodal-
ton (kDa) to the left. B, Secretion of Dkk1-4 into the cell culture superna-
tant. MOPC315.4 transfectants (1 × 104 cells/cm2) were cultured for 3 
days and 10 µl CM were analyzed by Western blotting using Ab to His6 
and Dkk1-4 as indicated. Note that Dkk2 was secreted as an apparent 
cleavage product (<17kDa) of the intracellular protein shown in panel A 
(~40 kDa). C, Dkk1 and -2 inhibit Wnt3a-induced stabilization of β-catenin 
in L cells. Dkk-CM was added to the cell culture medium at final concen-
trations of 5, 10, 20, 40 or 80 percent (v/v) as indicated at the bottom. 
Zero Dkk-CM designates samples supplemented with 20% M-CM. Three 
hours later, Wnt3a-CM (indicated by plus symbols in the 2nd line from the 
bottom) or L-CM (no Wnt3a; minus symbols) was added at a final concen-
tration of 10%. Cells were cultured for 3 h and β-catenin (β-cat) and β-
actin (β-act) were determined by Western analysis using 10 µg total pro-
tein per sample. D, Relative expression levels of β-catenin in L cells 
exposed to Wnt3a and Dkk1-4. Three immunoblots, including the one 
presented in panel C, were evaluated by densitometry and the ratio of β-
catenin to β-actin was determined. This ratio was defined as one (100%) in 
cells stimulated with Wnt3a but not exposed to Dkk. Asterisks indicate 
significant drops in β-catenin in Dkk-treated compared to untreated cells 
(p < 0.05).
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The ALP increase in C2C12 cells was not as pronounced
(2-fold) but clearly present (Fig. 2A left, top bar).
Treatment of both cell lines with Dkk1 and -2 resulted in
a significant drop in Wnt3a-induced ALP (Fig. 2A). Unlike
C2C12 cells, treatment of C3H10T1/2 cells with Dkk4 led
to a small but highly significant decrease in ALP. This indi-
cated that Dkk4 sometimes exhibited Wnt-inhibiting
activity, as mentioned above. Dkk3 was ineffective in both
cell lines, as expected (Fig. 2A). The ALP-inhibiting effect
of Dkk1 and -2 was confirmed at the level of gene tran-
scription using real-time RT-PCR (Fig. 2B). Just as in case
of ALP protein, Dkk1 was a potent inhibitor in both cell
lines, whereas Dkk2's inhibitory activity was more con-
vincing in C2C12 than in C3H10T1/2 cells. In contrast to
Dkk3 and -4 (results not shown), Dkk1 and -2 inhibited
the Wnt3a-dependent induction of OCN mRNA (Fig. 2C),
with Dkk2 being once again more potent in C2C12 than
C3H10T1/2 cells. These quantitative differences aside, the
results suggested that Dkk1 and -2 inhibit Wnt/β-catenin-
dependent osteoblast differentiation.
Dkk1 and -2 enhance BMP2-induced ALP expression
The developmental cues emanating from BMP signaling
must be integrated with inputs from Wnt and other signal
transduction pathways to properly orchestrate the net-
work of transcription factors that govern osteoblast differ-
entiation. Based on this consideration, we assessed
osteoblastogenesis under conditions of ongoing BMP or
Wnt/BMP signaling further modulated by the BMP inhib-
itor, Noggin, and the Wnt inhibitor, Dickkopf. Similar to
previous reports on BMP2-induced differentiation of pre-
osteoblasts [36,37], treatment of C2C12 cells with BMP2
led to a substantial induction of ALP protein (~150-fold,
Fig. 3A left, top bar) and ALP mRNA (~6000-fold, Fig. 3A
right, top bar). This response was abrogated by Noggin
(2nd bar from bottom), indicating that ALP induction was
dependent on BMP signaling. Surprisingly, we also found
that in BMP2-stimulated cells, addition of Wnt3a resulted
in a significant down-regulation of ALP (Fig. 3A, 2nd bar
from top), even though Wnt3a weakly induced ALP in
absence of BMP2 (Fig. 2A). Treatment of BMP2-stimu-
lated C2C12 cells with Dkk1 led to a more than two-fold
increase in ALP protein (Fig. 3A left, 3rd bar from top), not
a decrease as reported elsewhere [27]. The increase was
blunted by Wnt3a (Fig. 3A left, 4th bar), indicating that
the Dkk1 effect was indeed dependent upon Wnt signal-
ing, not caused by some unrelated property of this inhib-
itor. Dkk2 shared the above-described activities of Dkk1,
while Dkk3 and -4 were ineffective (data not shown).
These results indicated that in BMP2-stimulated osteopro-
genitors the Wnt3a-dependent inhibition of ALP is par-
tially abrogated by Dkk1 and -2.
Dkk1 and -2 enhance BMP2-induced Osterix expression
Because transcription factors Cbfa1, Osterix and ATF4 are
instrumental for the cell fate decision that commits mes-
enchymal progenitors to undergo differentiation to oste-
oblasts [30,31,38], we sought to determine whether
Wnt3a/BMP2 signaling influences the expression of these
Dkk1 and -2 inhibit Wnt3a-induced expression of osteoblas- tic differentiation markers in C2C12 cells (left) and  C3H10T1/2 cells (right) Figure 2
Dkk1 and -2 inhibit Wnt3a-induced expression of 
osteoblastic differentiation markers in C2C12 cells 
(left) and C3H10T1/2 cells (right). A, Inhibition of 
Wnt3a-induced ALP activity by Dkk1 and -2 in cell lines 
C2C12 (grey columns) and C3H10T1/2 (white columns). Cells 
were pre-incubated for 3 h with Dkk1-4-CM or M-CM. 
Wnt3a-CM was added and cells were cultured for six days. 
L-CM was used in control experiments to determine the 
baseline level of ALP in cells not stimulated with Wnt3a (not 
shown). ALP activity was measured by ELISA and values were 
normalized to total protein. Results are presented as fold 
induction relative to cells not stimulated with Wnt3a. Data 
are means ± SD from three independent experiments. Aster-
isks indicate significant decreases (p < 0.005) compared to 
cells not treated with Dkk. B, Inhibition of Wnt3a-induced 
ALP mRNA by Dkk1 and -2. Experimental setup was the 
same as described in panel A except cells were stimulated 
with Wnt3a for 3 rather than 6 days. ALP mRNA was deter-
mined by real-time RT-PCR and normalized to the message 
levels of β-actin mRNA. Data are means ± SD from three 
independent experiments. One asterisk (p < 0.05) and two 
asterisks (p < 0.005) denote a significant loss of ALP message 
compared to cells not treated with Dkk. C, Inhibition of 
Wnt3a-induced OCN mRNA expressions by Dkk1 and -2. 
Experimental setup was the same as described in panel A. 
OCN mRNA was determined by real-time RT-PCR and nor-
malized to β-actin message levels. Data are means ± SD from 
three independent experiments. One asterisk (p < 0.05) and 
two asterisks (p < 0.005) denote a significant drop in OCN 
message relative to cells not treated with Dkk.
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transcription factors in differentiating C2C12 cells. Using
real-time RT-PCR, we found that BMP2 caused but a mod-
est (2-fold) increase in Cbfa1 mRNA (Fig. 3B left, top bar),
yet a substantial (~60-fold) elevation in Osterix mRNAs
(Fig. 3B right, top bar). ATF4 message was unchanged
(data not shown). The induction of the Cbfa1 and Osterix
genes was inhibited by Noggin (2nd bar from bottom),
indicating that the transcriptional activation relied on
BMP2 signaling. Similar to ALP, the expression of Osterix,
but not Cbfa1, was down regulated by Wnt3a (Fig. 3B
right, 2nd bar from top). Treatment of BMP2- or BMP2/
Wnt3a-stimulated cells with Dkk1 resulted in both cases
in a marked elevation of Osterix message (3rd bar and 4th
bar, respectively), further indicating that Wnt signaling is
a suppressor of Osterix. Dkk2 shared the above-described
activities of Dkk1, while Dkk3 and -4 were ineffective
(data not shown). These findings suggested that Wnt/β-
catenin inhibits BMP2-dependent induction of Osterix in
osteoprogenitors.
Wnt3a restores BMP2-dependent loss of p53
Osterix expression in osteoblasts has been recently shown
to be negatively regulated by p53 [32]. We therefore spec-
ulated that the BMP2- or Wnt3a-dependent up- or down-
regulation of Osterix may be accompanied by correspond-
ing changes in p53 levels: decrease of p53 in case of BMP2
treatment and increase of p53 in case of treatment with
Wnt3a. To evaluate this, we determined p53 in C2C12
cells using Western blotting. Lysate from untreated cells
contained levels of p53 that were markedly reduced upon
treatment with BMP2 (Fig. 3C, lanes 1 and 2). Treatment
of cells with Wnt3a, which left the p53 baseline essentially
unaffected (lane 3), restored p53 to near baseline levels in
the presence of BMP2 (lane 4). Addition of Dkk1 or -2 did
not alter the levels of p53 in Wnt3a-stimulated cells (com-
pare lanes 7 and 11 with lane 3), but slightly attenuated
the Wnt3a-dependent restoration of p53 under condi-
tions of ongoing BMP2 signaling (compare lanes 8 and 12
with lane 4). Since p53 is a positive regulator of p21
expression, we next examined whether the BMP2-depend-
ent loss of p53 was associated with the reduction of p21.
Figure 3C (center) shows that this was the case. In fact, the
changes of p21 closely matched those of p53 regardless of
the specific treatment condition. These findings suggested
that Wnt/β-catenin signaling by itself is not important for
the regulation of p53/p21 in preosteoblasts. However, in
cells undergoing BMP2 signaling, the Wnt/β-catenin path-
way functions as a strong antagonist of the BMP-mediated
suppression of p53.
Dkk1 and -2 inhibit Wnt3a-induced OPG production
Wnt3a/β-catenin signaling has been reported to induce
OPG transcription in C3H10T1/2 cells [13], but this has
not yet been extended to C2C12 cells, and the influence of
Dkk proteins and ongoing BMP2 signaling on OPG
expression are also unknown in both cell types. To that
end, we found that treatment of C2C12 cells with Wnt3a
resulted in a 6-fold induction of OPG mRNA (Fig. 4A, 2nd
bar from top). This induction was abrogated by Dkk1 (3rd
bar) and strongly inhibited by Dkk2 (4th bar). Dkk3 and -
Wnt3a inhibits ALP and Osterix, but restores p53, in BMP2- stimulated C2C12 cells Figure 3
Wnt3a inhibits ALP and Osterix, but restores p53, in 
BMP2-stimulated C2C12 cells. A, Wnt3a diminishes 
BMP2-dependent expression of ALP. Cells were pre-cultured 
for 3 h with M-CM (not containing Wnt or BMP inhibitor), 
Dkk1-CM, or M-CM supplemented with 100 ng/ml Noggin as 
indicated. L-CM (no Wnt3a) supplemented with 100 ng/ml 
BMP2 (white columns) or Wnt3a-CM supplemented with the 
same amount of BMP2 (black bar) was added and cells were 
cultured for 3 days in case of mRNA measurement or 6 days 
in case of protein determination. Assays were performed as 
described in Figure 2. Results are presented as fold induction 
relative to cells not stimulated with BMP2 or BMP2/Wnt3a. 
Data are means ± SD from three independent experiments. 
Asterisks and number signs indicate significant changes (p < 
0.005) compared to treatment with BMP2 only (top bar) and 
BMP2 plus Wnt3a (2nd bar from top), respectively. B, Wnt3a 
inhibits BMP2-induced expression of Osterix but leaves 
Cbfa1 unchanged. Message levels of both genes were deter-
mined by real-time RT-PCR. Cells were treated and results 
are presented as described in panel A. C, Wnt3a mitigates 
the BMP2-dependent loss of p53. Cells were cultured for 3 
days as indicated in panel A. Protein levels of p53 (top), p21 
(center) and β-actin (bottom) were determined by Western 
blotting using 20 µg cell lysate per lane. The same result was 
obtained in two additional experiments (not shown).
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4 were ineffective (not shown). Similar findings were
obtained with C3H10T1/2 cells (not shown). To further
validate these results, we used ELISA to measure the
amount of OPG protein secreted into the cell culture
supernatant. There was a good match of OPG message
and protein (Fig. 4B) for all four treatment conditions.
The same result was obtained with C3H10T1/2 cells (not
shown). We next measured OPG mRNA in BMP2-stimu-
lated and BMP2/Wnt3a-costimulated C2C12 cells. BMP2
decreased OPG mRNA below the level seen in the control
(Fig. 4C top, 2nd bar). The decrease was abolished by Nog-
gin (3rd bar), but not by Dkk1 (4th bar). Wnt3a partially
restored the level of OPG mRNA held down by treatment
of cells with BMP2 (Fig. 4C bottom, 2nd bar). The restora-
tion was abolished by Dkk1 (4th bar), but not by Noggin
(3rd bar). These results demonstrated that OPG is regu-
lated by both Wnt/β-catenin and BMP2 signaling. The
Wnt pathway induces OPG, whereas the BMP2 pathway
suppresses OPG. Interestingly, Dkk1 kept OPG low irre-
spective of the BMP2 signaling status (on or off). This
pointed to a mechanism by which Dkk1 may promote
osteolytic lesions in vivo: enhancement of RANKL-medi-
ated osteoclastogenesis.
Wnt3a suppresses basal and 1,25(OH)2D3-induced 
RANKL, but not BMP2-induced RANKL
Wnt/β-catenin signaling has been demonstrated to down-
regulate RANKL mRNA in MC3T3-E1 preosteoblast [14],
but thus far this situation has not been studied in C2C12
or C3H10T1/2 cells. The influence of Dkk proteins on
RANKL expression and the outcome of possible crosstalk
of the Wnt, BMP2 and 1,25(OH)2D3 signaling pathways
are also unknown. On this backdrop, we found that
Wnt3a repressed RANKL mRNA in C2C12 cells (Fig. 5A)
and C3H10T1/2 cells (results not shown). In both cell
lines RANKL suppression was mitigated by Dkk1, whereas
Dkk2, -3 and -4 and Noggin were ineffective (Fig. 5A and
data not shown). Wnt3a also repressed 1,25(OH)2D3-
induced RANKL mRNA expression in C2C12 cells (Fig.
5B), which was partially reversed by Dkk1 but not by Nog-
gin (Fig. 5B), indicating involvement of the Wnt/β-cat-
enin pathway. BMP2 increased RANKL mRNA in C2C12
cells (Fig. 5C), which was inhibited by Noggin, as
expected. Importantly, because Wnt3a was unable to
down regulate the BMP2-dependent induction of RANKL,
the addition of Dkk1 to this system was inconsequential
(Fig. 5C). This indicated that in contrast to 1,25(OH)2D3-
stimulated and untreated C2C12 cells, cells undergoing
BMP signaling become unresponsive to Wnt/β-catenin's
inhibiting effects on RANKL expression.
Dkk1 abrogates the suppressive effect of Wnt3a on M-CSF 
production in BMP2-stimulated cells
Osteoblast-produced M-CSF, a positive regulator of oste-
oblast-dependent osteoclast development, might be influ-
Dkk1 and -2 inhibit Wnt3a-induced OPG expression in  C2C12 cells Figure 4
Dkk1 and -2 inhibit Wnt3a-induced OPG expression in 
C2C12 cells. A, Inhibition of Wnt3a-induced OPG mRNA by Dkk1 
and -2. Cells were pre-cultured in Dkk1- or Dkk2-CM for 3 h as indi-
cated. M-CM (no Dkk) was used for the two samples at the top. 
Wnt3a-CM or L-CM (no Wnt 3a; control) was added and cells were 
grown for 3 days. Total RNA was extracted and OPG mRNA was 
determined using real-time RT-PCR. Message levels were normalized 
using β-actin mRNA as reference. Results are presented as fold induc-
tion relative to the control. Data are shown as means ± SD based on 
5 independent experiments. Number signs and asterisks indicate sig-
nificant changes (p < 0.005) compared to cells not treated with Wnt3a 
(top bar) and treated with Wnt3a (2nd bar from top), respectively. B, 
Dkk1 and -2 dependent inhibition of Wnt3a-induced OPG protein 
secreted into the extracellular milieu. Cells were treated as described 
above, supernatant was harvested, and OPG was determined using 
ELISA. Results are presented as in panel A. C, Wnt3a-dependent OPG 
induction is inhibited by BMP2. Cells were pre-incubated for 3 h with 
Dkk1-CM or M-CM supplemented with 100 ng/ml Noggin where indi-
cated. Cells were grown for 3 days in L-CM (top panel) or Wnt3a-CM 
(bottom panel) that contained 100 ng/ml BMP2 where indicated. OPG 
mRNA was measured and results were calculated as described in 
panel A. Number signs, asterisks and paragraph symbols indicate sig-
nificant changes (p < 0.005) compared to untreated cells (control), 
BMP2-treated cells and BMP2/Wnt3a-treated cells, respectively. Note 
that the bars labeled Control (black) and Wnt3a (green) in this panel 
are identical to corresponding bars in panels A and B.
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enced by Wnt or BMP2 signaling in mesenchymal stem
cells undergoing osteoblastic differentiation. To investi-
gate this, we used C2C12 as the model system and real-
time PCR as the measurement tool. We found that Wnt3a
repressed M-CSF mRNA compared to the control (Fig. 6A,
2nd bar from top). Unlike Noggin, Dkk1 restored the M-
CSF message, further indicating that M-CSF is down regu-
lated by Wnt/β-catenin signaling in this cell type. ELISA of
C2C12 cell culture supernatant confirmed these findings
at the level of secreted, soluble M-CSF protein (Fig. 6B).
We next evaluated M-CSF production in C2C12 cells
undergoing BMP2 and Wnt3a/BMP2 signaling further
modulated by Noggin and Dkk1. BMP2 enhanced M-CSF
by a factor of two (Fig. 6C top). Noggin, but not Dkk1,
blocked the response. Wnt3a repressed the BMP2-induced
increase of M-CSF in a manner that was reversed by Dkk1
but not Noggin (Fig. 6C bottom), confirming that the
Wnt/β-catenin pathway is a negative regulator of M-CSF.
FACS analysis of the same cell preparation evaluated in
panel C demonstrated a good match of the secreted and
membrane-associated forms of M-CSF (Fig. 6D). These
results demonstrated that M-CSF expression in osteoblast
progenitors is up and down regulated by BMP and Wnt/β-
catenin signaling, respectively. Dkk1 stabilized M-CSF
expression levels in presence and absence of BMP2, sug-
gesting yet another mechanism by which Dkk1 activates
osteoclast development in vivo.
Discussion
The present study used mesenchymal progenitor cells
undergoing osteoblastic differentiation in vitro to demon-
strate that Wnt inhibitors Dkk1 and -2 and, to a lesser
extent, Dkk4 enhance the osteoclastogenic potency of
early osteoprogenitors. The underlying mechanism
appears to involve at least two aspects of Dickkopf biol-
ogy. The first concerns the restoration of the Wnt/β-cat-
enin-induced reduction of M-CSF in BMP2-stimulated
osteoprogenitors. The second involves the ability of Dkk1
and -2 to mitigate the Wnt/β-catenin-dependent down-
regulation of RANKL (observed in 1,25(OH)2D3-stimu-
lated osteoprogenitors) and the concomitant up-regula-
tion of its inhibitor, OPG (seen in BMP2-induced
osteoprogenitors). We postulate that the resultant
changes in M-CSF/c-Fms and RANKL-RANK signaling
enhance osteoclast development in vivo; i.e., the differen-
tiation of monocytic precursors via pre-osteoclasts to
mature, activated osteoclasts. The Dkk1- and -2-depend-
ent changes in M-CSF, RANKL and OPG expression, and
the somewhat unexpected ability of Dkk1 and -2 to pro-
mote rather than inhibit certain aspects of osteoblastogen-
esis, will be discussed in greater depth in the following.
Our finding that Dkk1 and -2 abolished the Wnt3a-
dependent down regulation of ALP message and protein
in otherwise untreated (Fig. 2) or BMP2-stimulated
Dkk1 attenuates Wnt3a-dependent inhibition of RANKL in  C2C12 cells treated with 1,25(OH)2D3 or left untreated Figure 5
Dkk1 attenuates Wnt3a-dependent inhibition of 
RANKL in C2C12 cells treated with 1,25(OH)2D3or left 
untreated. A, Mitigation of Wnt3a-dependent suppression of 
RANKL message by Dkk1. Cells were pre-incubated for 3 h in 
Dkk1-CM or M-CM supplemented with 100 ng/ml Noggin. Plain 
M-CM was used for the two samples at the top (not indicated). 
Cells were grown for 3 days in Wnt3a-CM or L-CM without 
Wnt3a (control). Total RNA was extracted and mRNA levels of 
RANKL were determined using real-time RT-PCR. Data are 
shown as means ± SD based on 5 independent experiments. 
Number signs and asterisks designate a significant drop (p < 
0.005) compared to the control and Wnt3a-treated cells, 
respectively. B, Dkk1 partially restores the Wnt3a-mediated 
drop of RANKL mRNA in cells treated with 1,25(OH)2D3. Cells 
were pre-incubated as desribed in panel A and grown for 3 days 
in L-CM (no Wnt3a) or Wnt3a-CM supplemented with 10 nM 
1,25(OH)2D3. Data are shown as means ± SD based on 5 inde-
pendent experiments. Number signs, asterisks and paragraph 
symbols designate significant changes (p < 0.005) compared to 
untreated cells, 1,25(OH)2D3-treated cells and Wnt3a/
1,25(OH)2D3-treated cells, respectively. C, Wnt3a does not 
affect BMP2-dependent RANKL expression. Cells were pre-
incubated as described in panel A and grown for 3 days in Dkk1-
CM (2nd bar from bottom), M-CM supplemented with 100 ng/ml 
Noggin (bottom bar), or M-CM (3 top bars). Cells were grown 
for 3 days in L-CM (top bar), L-CM containing 100 ng/ml BMP2 
(2nd bar from top), or Wnt3a-CM supplemented with 100 ng/ml 
BMP2 (three bars at bottom). Data are shown as means ± SD 
from 3 independent experiments. Number signs and asterisks 
designate a significant elevation compared to untreated cells and 
a reduction compared to BMP2-treated cells (p < 0.005), 
respectively. Note that the bar labeled Control (green) in this 
panel is identical to corresponding bars in panels A and B.
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C2C12 and C3H10T1/2 cells (Fig. 3) indicated that
Wnt3a inhibits certain aspects of osteoprogenitor differ-
entiation  in vitro. The mitigating effects of Wnt3a in
BMP2-induced cells were consistent with results from
other investigators indicating extensive crosstalk of the
Wnt/β-catenin and BMP signaling pathways in pre-oste-
oblasts. Pertinent observations include the activation of
Wnt/β-catenin by BMP2 [39]; inhibition of BMP2-
induced ALP by Dkk1 [40]; conversely, enhancement of
BMP2-induced ALP by enforced expression of constitu-
tively active β-catenin [41]; and inhibition of Wnt3a-
dependent ALP by Noggin [42]. Recent work with mouse
C2C12 and human mesenchymal stem cells showed that
TGF-β1 inhibits BMP2-induced ALP in a manner that
involves the translocation of β-catenin to the cell nucleus
[43,44]. This has connected TGF-β signaling with the BMP
and Wnt/β-catenin pathways. Our findings are also in
agreement with the notion that Wnt/β-catenin inhibits
BMP2-dependent osteoprogenitor development by a
mechanism that relies on the nuclear translocation ofβ-
catenin, although this has not yet been formally demon-
strated.
Our observation that Wnt3a blocked the BMP2-induced
expression of Osterix [30] raised questions about the
mechanism by which Wnt/β-catenin suppresses BMP-
dependent osteoblast differentiation. We showed, for the
first time, that the expression of p53, a negative regulator
of Osterix [32], is down regulated by BMP2. Furthermore,
Wnt3a was able to restore the BMP2-dependent loss of
p53. These results supported the model that BMP2-
dependent osteoblast differentiation is controlled in large
measure by the p53-Cbfa1-Osterix-ALP axis (Fig. 7A).
Apparently, this axis is down modulated by crosstalk with
the Wnt/β-catenin pathway, the precise molecular mecha-
nism of which remains to be elucidated. An important
implication of our hypothetical scheme is that Dkk1 and
-2 may promote osteoblast differentiation by virtue of
releasing the β-catenin-dependent brake on the BMP-p53-
Cbfa1-Osterix-ALP pathway.
Expression of OPG in osteoblasts, a crucial factor for
maintaining normal bone mass, has been reported to be
regulated by Wnt/β-catenin signaling [11-13]. We con-
firmed this in three different types of osteoprogenitors
(results for MC3T3-E1 cells not shown); demonstrated for
the first time that Dkk1 and -2 inhibit the Wnt3a-induced
OPG expression at the mRNA and protein level; and fur-
ther showed that the BMP2-dependent repression of OPG
is not affected by Dkk1 or -2 (Fig. 4). Because osteoblast
development in vivo is likely to occur in the co-presence of
Wnt and BMP ligands, it seemed important to evaluate
OPG expression upon co-stimulation of cells with Wnt3a
and BMP2. Our results indicated that Wnt signaling pre-
dominates over BMP signaling in this regard. The increase
Dkk1 restores Wnt3a-dependent loss of M-CSF in C2C12  cells Figure 6
Dkk1 restores Wnt3a-dependent loss of M-CSF in 
C2C12 cells. A, Dkk1 restores Wnt3a-dependent decrease 
in M-CSF message. Cells were pre-incubated for 3 h in Dkk1-
CM, M-CM supplemented with 100 ng/ml Noggin, or plain M-
CM (two columns at the top). Cells were grown for 3 days in 
Wnt3a-CM or L-CM that did not contain Wnt3a (control). 
Total RNA was extracted and mRNA levels of M-CSF were 
determined using real-time RT-PCR. Data are shown as 
means ± SD based on 5 independent experiments. Number 
signs and asterisks indicate significant changes (p < 0.005) 
compared to untreated cells and Wnt3a-treated cells, 
respectively. B, Dkk1 restores Wnt3a-dependent decrease in 
M-CSF protein secreted into the extracellular milieu. Super-
natant was harvested and M-CSF was determined using 
ELISA. Cells were treated and results are presented as 
described above. C, Wnt3a-dependent loss of secreted M-
CSF is abrogated in BMP2-treated cells by Dkk1. Cells were 
pre-incubated as described in panel A. Cells were grown for 
3 days in L-CM (top panel) or Wnt3a-CM (bottom panel), both 
containing 100 ng/ml BMP2 where indicated. Cells cultured in 
L-CM (no Wnt3a) served as control. Supernatant was har-
vested and M-CSF was determined using ELISA. Results are 
shown as means ± SD based on 5 independent experiments. 
Number signs, asterisks and paragraph symbols denote signif-
icant differences (p < 0.005) compared to untreated cells, 
BMP2-treated cells and Wnt3a/BMP2-treated cells, respec-
tively. Note that the control here is identical to the control 
in panel B and that the top-most bar in the bottom panel is 
identical to the "Wnt3a" bar in panel B. D, Wnt3a-dependent 
loss of membrane-associated M-CSF is abrogated in BMP2-
stimulated cells by treatment with Dkk1. Cells were pre-
incubated and cultured as in panel C followed by FACS analy-
sis using antibody to M-CSF (open histograms) or isotype-
matched unrelated antibody (filled histograms). BMP2-stimu-
lated cells or cells left untreated demonstrated very small, if 
any, changes in surface M-CSF expression upon treatment 
with Dkk1. Cells co-stimulated with BMP2 and Wnt3a, how-
ever, showed a marked increase in M-CSF reactivity in pres-
ence of Dkk1. Similar results were obtained in three 
independent experiments.
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in OPG output in Wnt3a-treated cells was abolished by
Dkk1 and -2, suggesting that abnormally high levels of
Dkk1 or -2 in situ reduce the amount of OPG secreted into
the extracellular milieu. The resultant promotion of
RANKL-dependent osteoclastogenesis may contribute to
the development of lytic bone lesions in MM [27]. In sup-
port of this theory, MM patients generally exhibit reduced
OPG serum levels compared to healthy individuals, and
the number of lytic bone lesions is inversely correlated
with OPG [45,46].
Wnt/β-catenin signaling has been reported to attenuate
osteoclastogenesis by down modulating the important
regulator of bone homeostasis, RANKL [47], in osteopro-
genitors [14]. We extended this observation to the present
C2C12 and C3H10T1/2 cells and the 1,25(OH)2D3-
induced pathway of RANKL activation in these cells (Fig.
5). We further showed, for the first time, that M-CSF was
down regulated by Wnt/β-catenin in BMP2-stimulated
osteoprogenitors (Fig. 6). M-CSF is a positive regulator of
Osterix, which, in turn, down regulates p53 [32]. Our
observation that BMP2-regulated p53 levels were
inversely correlated with levels of Osterix and M-CSF sug-
gested that, just like ALP, M-CSF is controlled by the BMP-
p53-Osterix axis. Additional studies are warranted to vali-
date this hypothesis. Studying the impact of Wnt3a on
BMP2- or 1,25(OH)2D3-dependent expression of RANKL,
we noted that Wnt3a markedly diminished the
1,25(OH)2D3-induced RANKL but did not interfere with
the BMP2-induced RANKL. Thus, among different path-
ways of RANKL induction, only a subset appears to be
prone to down modulation by Wnt/β-catenin. Dkk1 and
-2 partially restored the Wnt3a-dependent reduction of
RANKL in cells treated with 1,25(OH)2D3, pointing to
another molecular mechanism by which canonical Wnt
inhibitors may promote osteoclastogenesis in situ.
This study systematically compared Dkk1 with the three
other members of the Dickkopf family. Although only
selected data are presented in this report, all experiments
involving Dkk1 also included Dkk2, -3 and -4. In agree-
ment with other studies [33,48], Dkk3 lacked activity in
any of the Wnt3a-mediated responses evaluated here. This
was different for Dkk2 and -4, which recapitulated some
features of Dkk1. Dkk2 tended to be more active in
C2C12 than C3H10T1/2 cells, whereas the opposite was
true for Dkk4. Considering the activity of Dkk2 and -4, it
is interesting to note that only Dkk1 has been implicated
thus far in cancer-associated bone lesions. Unlike Dkk2
and -4, Dkk1 binds to Kremen1/2, which leads to rapid
endocytosis of the Dkk1-LRP5/6-Kremen1/2 complex
[49]. This raises the possibility that Kremen is a critical co-
factor of Dkk1-dependent osteolysis that warrants further
investigation.
Conclusion
The present study further implicates impaired Wnt signal-
ing in the pathogenesis of cancer-associated lytic bone
lesions. Our results support the hypothesis that the consti-
tutive secretion of Dickkopf by tumor cells leads to focal
bone loss by a complex mechanism that involves
enhanced osteoclastogenesis (Fig. 7B). In vivo approaches
Hypothetical scheme of the mechanism by which Dkk1 pro- motes osteolytic lesions in vivo Figure 7
Hypothetical scheme of the mechanism by which 
Dkk1 promotes osteolytic lesions in vivo. A, The cellular 
differentiation of osteoprogenitors, which can be monitored 
by Osterix and ALP expression, is governed in part by 
Wnt3a and BMP2 signaling. BMP2, which is inhibited by Nog-
gin, is a strong inducer of Osterix and ALP, relying on an indi-
rect mechanism that involves p53 and Cbfa1 (not included). 
Wnt3a/β-catenin signaling, which is antagonized by Dkk1 
(and Dkk2), can have opposing effects on osteoblast develop-
ment depending on BMP2 signaling. In absence of BMP2, 
Wnt3a weakly promotes osteoblast differentiation through 
the β-catenin pathway. In presence of BMP2, Wnt3a inhibits 
osteoblast differentiation by down-regulating the BMP2-p53-
Cbaf1-Osterix-ALP axis (thick line). The molecular mecha-
nism of the crosstalk has not yet been elucidated. Our 
scheme postulates that the Dkk1-dependent inhibition of 
Wnt3a's positive effect on osteoprogenitors in vitro may be 
outweighed by the abrogation of Wnt3a's negative effect on 
BMP2 signaling, such that, on balance, Dkk1 enhances fea-
tures of early osteoblastogenesis. B, The differentiation of 
osteoclasts, which is strictly dependent upon interaction of 
osteoclast precursors with osteoblasts, is mediated in part by 
signaling pathways that emanate from the binding of M-CSF 
and RANKL to c-Fms and RANK, respectively. Osteoblasts 
stimulated by BMP2 express high levels of M-CSF and 
RANKL (positive regulators of osteoclastogenesis) but low 
levels of OPG (negative regulator of osteoclastogenesis), 
resulting in a positive signal for osteoclast formation. Oste-
oblasts exposed to Wnt3a exhibit the opposite phenotype 
with regard to M-CSF, RANKL and OPG expression, result-
ing in a negative signal for osteoclast formation. Osteoclas-
togenesis is further dampened by Wnt3a's ability to inhibit 
BMP2 signaling, as indicated in panel A (thick line). Constitu-
tive expression of Dkk1 (and Dkk2) by bone marrow-homing 
tumor cells (e.g., multiple myeloma) may enhance osteoclas-
togenesis in vivo by inhibiting Wnt3a, thus shifting the balance 
of Wnt3a/BMP2 co-signaling in favor of BMP2 signaling. The 
consequent increase in osteoclastogenesis promotes lytic 
bone lesions as long as the paracrine supply of Dkk1 by 
tumor (myeloma) cells is sustained.
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will be necessary to further test this hypothesis. To that
end, the Dkk1-4-secreting sublines of the mouse plasma-
cytoma MOPC315 developed here may provide a starting
point, as the tumor cells can be readily transplanted into
BALB/c mice where they infiltrate the bone marrow
(results not shown) and, possibly, cause osteolytic lesions
in dependence on Dickkopf expression. Pre-clinical stud-
ies of this sort may also facilitate the development of
small-drug Dkk inhibitors that may be useful not only for
the treatment and prevention of cancer-associated bone
loss, but also for treatment of osteoporosis, periodontal
disease and bone destruction consequent to rheumatoid
arthritis. Success will require further assessment of the
molecular properties of the various Dkk's, their specific
activities in different target cells, and thorough under-
standing of the regulatory loops between signaling path-
ways and cell populations affected by Wnt signaling in
bone.
Methods
Cell lines and cell culture
Mouse plasmacytoma MOPC315.4 [50], a generous gift
from Dr. B. Bogen (University of Oslo, Oslo, Norway),
was cultured in RPMI 1640 containing 10% fetal bovine
serum (FBS), 2 mM glutamine, 50 µM 2-mercaptoetha-
nol, and antibiotics (100 U/ml penicillin, 100 µg/ml
streptomycin). Plat-E cells [51] were kindly provided by
Dr. T. Kitamura (Institute of Medical Science, University
of Tokyo, Tokyo, Japan) and maintained in Dulbecco's
modified Eagle's medium (DMEM) containing 10% FBS,
2 mM glutamine, 10 µg/ml blasticidin, 1 µg/ml puromy-
cin, and antibiotics. C2C12 and C3H10T1/2 are mesen-
chymal stem cells obtained from ATCC (Manassas, VA).
Wnt3a-expressing L cells (L-Wnt3a) and the correspond-
ing parental cell line, L, were also purchased from ATCC.
Cells were maintained in α-minimal essential medium in
the case of C3H10T1/2 cells or DMEM in the case of
C2C12, L-Wnt3a and L cells. Both media were supple-
mented with 10% FBS, 2 mM glutamine, and antibiotics.
All cell culture media and supplements were obtained
from Invitrogen (Carlsbad, CA). All cells were cultured in
a humidified atmosphere at 37°C and 5% CO2.
MOPC315.4 producing Dkk
The cDNAs encoding Dkk1 and -4 were cloned by PCR,
using a mouse embryonic cDNA library (Open Biosys-
tems, Huntsville, AL) as template. Dkk2 and -3 cDNAs
were obtained by reverse transcriptase-PCR, using total
RNA from mouse uterus and brain, respectively, as tem-
plate. All four cDNAs were modified by adding C-terminal
FLAG or His6 epitope tags, sequenced, and subcloned into
the retroviral expression vector pMY-IRES-EGFP [52]
kindly provided by Dr. T. Kitamura (Institute of Medical
Science, University of Tokyo). pMY-IRES-EGFP without
Dkk insert was used as control. Retrovirus was produced
by transient transfection of Plat-E cells. Briefly, 1.6 × 106
cells were plated in DMEM in 60-mm cell culture dishes
for 30 h prior to transfection with retrovirus. Using Lipo-
fectamine 2000 (Invitrogen), cells were transfected with 8
µg of one of the four Dkk expression vectors or the
"empty" GFP control vector. The viral supernatant was
harvested 16 h later and filter-sterilized. For retroviral
infection, 5 × 105 MOPC315.4 cells were cultured for 16 h
in a 6-well plate that contained equal volumes of cell cul-
ture medium and retroviral supernatant supplemented
with 10 µg/ml polybrene (Sigma, St. Louis, MO). Cells
were washed and cultured for 3 days, followed by isola-
tion of virally infected, green fluorescent protein (GFP)
expressing cells using a FACSCalibur and the CellQuest
software (Becton Dickinson, Franklin Lakes, NJ).
Conditioned media containing Dkk and Wnt3a
Medium conditioned with Dkk1, -2, -3 or -4 (hereafter
referred to Dkk-CM) was obtained from flow-sorted GFP+
plasmacytoma cells. Briefly, 7.5 × 105 cells were seeded in
75 cm2 flasks containing 25 ml RPMI 1640 supplemented
with 10% FBS. After 3 days in culture, supernatant was
harvested, filter-sterilized, and stored at 4°C. Medium
conditioned with Wnt3a (Wnt3a-CM) was prepared from
commercially available L-Wnt3a cells [34]; 1 × 106 cells
were seeded in 100-mm plates containing 10 ml DMEM
supplemented with 10% FBS. After cell culture for 4 days,
the supernatant was harvested, sterilized, and stored at
4°C. Medium conditioned with flow-sorted GFP+Dkk-
plasmacytoma cells (M-CM) and parental L cells (L-CM)
were used as controls for experiments with Dkk1-4 and
Wnt3a, respectively.
Western Blotting
Cells were incubated on ice for 20 min in CelLytic-MT
(Sigma) supplemented with a proteinase inhibitor cock-
tail (Roche, Indianapolis, IN) followed by centrifugation
at 12,000 × g for 20 min to prepare whole cell lysate. Pro-
tein concentration was determined with the help of the
Bio-Rad Protein assay using BSA as standard (Bio-Rad
Laboratories, Hercules, CA). Protein (10 µg lysate or 10 µl
CM) was incubated for 10 min at 70°C in sample buffer
containing reducing reagents; fractionated by SDS-PAGE
using 4–12% NuPAGE gels in MES buffer (Invitrogen);
transferred to a polivinylidene fluoride membrane (Invit-
rogen); blocked with StartingBlock T20 buffer (Pierce,
Rockford, IL); labeled with un-conjugated primary anti-
body followed by horseradish peroxidase-conjugated sec-
ondary antibody; and visualized with the enhanced
chemiluminescence detection system (GE Health Sci-
ences, Piscataway, NJ). The following antibodies/-sera
were used: mouse monoclonal to β-actin or FLAG
(Sigma), GFP (MBL, Woburn, MA), His6 (Invitrogen), or
p21 (BD PharMingen); rat monoclonal to Dkk1 or -3 andMolecular Cancer 2007, 6:71 http://www.molecular-cancer.com/content/6/1/71
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goat anti-Dkk2 or -4 (R&D Systems, Minneapolis, MN);
rabbit anti-p53 (Vector Laboratories, Burlingame, CA).
β-catenin stabilization
Wnt3a-dependent stabilization of β-catenin was deter-
mined as described elsewhere [35]. L cells (4 × 105) were
seeded in a 6-well plate, incubated for 24 h, washed, and
transferred to 1 ml Dkk-CM or M-CM (control). Follow-
ing incubation for 3 h, Wnt3a-CM or L-CM was added for
3 h. Cells were lysed in 50 µl lysis buffer. β-catenin was
determined by immunoblotting using 10 µg protein as
sample and mouse monoclonal anti-β-catenin from BD
transduction Laboratories as detection tool. β-catenin lev-
els were quantified by densitometry using NIH Image
software. β-catenin expression was normalized by com-
parison to the housekeeping protein, β-actin.
Osteoblast differentiation
Cells were seeded at 2 × 104 cm-2 one day prior to differen-
tiation induction. Cell culture medium was replaced with
α-minimal essential medium supplemented with 50 µg/
ml ascorbic acid and Dkk-CM, BMP inhibitor (100 ng/ml
mouse Noggin [R&D Systems]) or no inhibitor (M-CM).
Following pre-incubation for 3 h, cell differentiation was
induced by adding Wnt3a-CM and/or L-CM that either
contained 100 ng/ml recombinant human BMP2 (R&D
Systems) or 10 nM 1,25-dihydroxyvitamine D3
(1,25(OH)2D3, Sigma). Cells were cultured for 3 days (if
longer, the differentiation-inducing medium was replaced
after 3 days). In some experiments, differentiation
occurred in presence of Dkk-CM and/or 100 ng/ml Nog-
gin. Dkk-CM and Wnt3a-CM were added to a final con-
centration of 20% (v/v), which had been found in pilot
studies to result in optimal assay performance in our
hands (results not shown).
Alkaline Phosphatase (ALP)–ALP activity was determined in
cells that had been cultured in 24-well plates for 7 days.
Cells were washed twice with phosphate-buffered saline,
scraped off the plastic surface with a rubber policeman,
and lysed for 15 min in 100 µl Passive Lysis Buffer
(Promega, Madison, WI). Cell lysate was spun down at
12,000 × g for 5 min and enzyme activity was determined
at 37°C with the ALP LabAssay (Wako Pure Chemical,
Tokyo, Japan). Enzyme activity was normalized using
total protein (Bio-Rad assay) as reference.
Real-time RT-PCR
Total RNA was isolated using the RNeasy mini kit (Qia-
gen, Valencia, CA) supplemented with DNase. First-strand
cDNA synthesis was performed using the Superscript III
kit (Invitrogen) with 1 µg RNA as template. Real-time PCR
was carried out with the ABI 7500 cycler (Applied Biosys-
tems, Foster City, CA). Briefly, 12.5 µl SYBR green PCR
master mix (Applied Biosystems) and 5 µl cDNA (five- to
ten-fold dilutions of original sample) were added to 200
nM forward and reverse PCR primers in 96-well micro-
plates. Following thorough heat denaturation for 10 min
at 95°C, cDNA was amplified in 40 two-step cycles using
the following temperature protocol: 95°C for 15 s and
60°C for 60 s. PCR primer sequences and length of ampli-
cons are listed in Table 1. PCR primers were designed by
Roche Applied Science as part of their Universal
ProbeLibrary. All PCR reactions were performed in tripli-
cates. Results were normalized using β-actin message as
reference.
Enzyme-linked immunosorbent assay (ELISA)
Cell culture supernatant was harvested 3 days after initia-
tion of osteoblast differentiation as described above.
OPG, RANKL and M-CSF were determined by sandwich
ELISA, using the respective Duo-Sets from R&D Systems.
Flow cytometry of M-CSF expression
Cells (1 × 106) were incubated with 0.25 µg biotinylated
monoclonal rat antibody to mouse CSF-1 (BD PharMin-
gen) for 1 h at 4°C, followed by incubation with phyco-
erythin-labeled avidin (eBioscience, San Diego, CA). After
washing in phosphate-buffered saline, cells were analyzed
on a FACSCalibur using the CellQuest software for data
evaluation. Biotinylated rat IgG2a (eBioscience) was used
as control for unspecific antibody binding.
Table 1: Primer sequences used for real-time PCR
Target 
mRNA
Forward primer (5'→ 3') Reverse primer (5'→ 3') Product size 
(bp)
β-actin TGACAGGATGCAGAAGGAGA CGCTCAGGAGGAGCAATG 75
ALP AAGGCTTCTTCTTGCTGGTG GCCTTACCCTCATGATGTCC 61
ATF4 ATGATGGCTTGGCCAGTG TCTCCAACATCCAATCTGTCC 72
Cbfa1 GATGACACTGCCACCTCTGA GCCCAGTTCTGAAGCACCT 81
M-CSF CAGCTGCTTCACCAAGGACT TCATGGAAAGTTCGGACACA 60
OCN AGACTCCGGCGCTACCTT CTCGTCACAAGCAGGGTTAAG 93
OPG ATGAACAAGTGGCTGTGCTG CAGTTTCTGGGTCATAATGCAA 106
Osterix TTTAAACAAACACGATGATGATGA ATTGGACTTCCCCCTTCTTG 138
RANKL TGAAGACACACTACCTGACTCCTG CCACAATGTGTTGCAGTTCC 83Molecular Cancer 2007, 6:71 http://www.molecular-cancer.com/content/6/1/71
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Statistical analysis
Mean values and standard deviations (SD) were calcu-
lated and compared using ANOVA followed by Dunnett's
multiple comparison t-test. p values less than 0.05 were
considered significant.
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sFrp, secreted frizzled-related proteins
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